Somaxon Pharmaceuticals, Inc.
SOMX today announced that its licensee Paladin Labs Inc.
has received approval from Health Canada of Paladin's New Drug Submission
(NDS) for Silenor^® (doxepin) for the treatment and symptomatic relief of
insomnia characterized by frequent nocturnal awakening and/or early morning
awakenings.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
